BioNano Genomics Inc vs Progressive Corp — how do they compare? BioNano Genomics Inc trades at $1.17 (market cap $13.66M), while Progressive Corp trades at $209.22 (market cap $123.45B). The key difference: Progressive Corp is far larger — about 9037.3× BioNano Genomics Inc's market cap, and Progressive Corp pays a 6.55% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | PGR | |
|---|---|---|
Market Cap | $13.66M | $123.45B |
Sector | Health | Financials |
52-Week High | $4.92 | $252.68 |
52-Week Low | $1.06 | $190.40 |
Enterprise Value | $16.26M | $131.66B |
Dividend Yield | — | 6.55% |
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.16 with a bullish technical signal supported by moving averages. The company shows improving financial trends with narrowing losses and consistent earnings beats, though it remains unprofitable with negative margins. Recent news highlights operational progress including debt retirement and scientific publications. Valuation ratios appear attractive with P/S of 0.31 and P/B of 0.36.
The outlook remains speculative given persistent losses, but improving cash flow trends and analyst optimism provide catalysts. Key risks include ongoing negative profitability and competitive pressures in genomics. With 57% analyst buy ratings and bullish technical momentum, the stock offers high-risk growth potential for investors comfortable with biotech volatility.
Progressive (PGR) trades at $213.95, down 0.64% on the day, with a bullish technical outlook supported by moving averages. The company shows strong fundamental performance with revenue growing from $49.6B in 2022 to $87.6B in 2025 and net income reaching $11.3B. Recent Q2 2026 earnings beat expectations at $4.85 per share, though the combined ratio widened to 87.1%, indicating potential growth trade-offs. Analyst consensus price target stands at $231.20 with 37% buy ratings.
PGR presents a compelling investment case with reasonable valuation (P/E 10.65) and strong profitability (ROE 34.94%), though investors face risks from competitive pressures and potential margin compression as the company expands its bundled insurance offerings. The stock offers 8% upside to consensus target with balanced risk-reward profile.
Trailing returns across standard periods
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →